Obesity drugs are medicines that help people lose weight. Ozempic and Wegovy are two popular obesity drugs made by a company called Novo Nordisk. They have been very successful, so the company has decided to use some of its money to fund a new project. This project is creating a supercomputer powered by Nvidia's AI technology. A supercomputer is a very powerful computer that can do lots of complex calculations quickly. This supercomputer will be used for research and development in the field of medicine, especially weight loss drugs. It will help scientists find new ways to fight obesity and other health problems. Read from source...

- The article title suggests a causal relationship between obesity drugs and Nvidia, but the body does not provide any evidence or explanation for this claim. It is unclear how the success of Ozempic and Wegovy directly leads to the funding of Gefion supercomputer by Novo Nordisk Foundation.
- The article uses vague terms such as "revolutionize", "speed" and "efficiency" without providing any quantitative or comparative data to support these claims. It is unclear what benchmarks or criteria are used to measure the impact of Gefion on drug discovery and healthcare solutions.

1. Invest in Novo Nordisk (NVO) for long-term growth potential due to its success with obesity drugs like Ozempic and Wegovy, which are driving demand for its products and increasing revenues. The company has a strong pipeline of new drugs and is also investing in AI and digital technologies to accelerate drug development and improve patient outcomes.